Table 1.

Selection of hybrid molecules designed as potential antimalarial drugs.

(Abbreviations: ATQ: atovaquone (clinically approved), ART: artemisinin derivative (clinically approved), MF: mefloquine (clinically approved), TCS: triclosan (approved antiseptic), PQ: primaquine (clinically approved), NHC: N‐heterocyclic carbene, proca: procainamide, FAS‐II: fatty acid synthase‐II, HDAC: histone deacetylase, TrxR: thioredoxine reductase, DNMT: DNA methyl transferase, GR: glutathione reductase)